Weight-Loss drug trial for pancreatic cancer stalls
NCT ID NCT04844970
First seen Nov 17, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested a drug called anamorelin to see if it could help prevent weight loss and improve appetite in people with advanced pancreatic cancer who were starting chemotherapy. The trial planned to enroll about 100 participants but was stopped early with only 4 people taking part. The goal was to measure weight change and appetite symptoms over 25 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lahey Hospital & Medical Center
Burlington, Massachusetts, 01805, United States
Conditions
Explore the condition pages connected to this study.